Diamyd Medical partners with DiaUnion to recruit participants for Type 1 diabetes prevention trial posted on PRNewsWire.com, 7 November 2023.

Diamyd Medical has entered into a collaboration agreement with DiaUnion, a center of excellence in type 1 diabetes, to identify participants for the DiaPrecise trial, an open-label trial evaluating the safety, feasibility, and immune response of intralymphatic injections of Diamyd® in children at risk of developing type 1 diabetes who also carry the HLA DR3-DQ2 genotype. The DiaPrecise trial has been initiated and is ongoing at the Department of Clinical Sciences at Lund University, Malmö, with Markus Lundgren M.D., PhD, as the Principal Investigator.

“We are thrilled to partner with DiaUnion around the precision medicine trial DiaPrecise”, says Ulf Hannelius, President & CEO of Diamyd Medical. “An infrastructure for screening of type 1 diabetes is a prerequisite to evaluate preventive treatments, and this partnership is important to advance our goal of delaying or preventing the progression of type 1 diabetes with the antigen-specific immunotherapy Diamyd”.

DiaPrecise is the first precision prevention trial with Diamyd, and is conducted under the ASSET program (AI for the Sustainable Prevention of Autoimmunity in Society, www.asset.healthcare) funded by the Swedish Innovation Agency VINNOVA. DiaUnion is a consortium coordinated by the Medicon Valley Alliance involving also the Steno Diabetes Center Copenhagen and Lund University, Malmö, establishing a screening program to identify individuals positive for diabetes autoantibodies, and those at high risk for the disease.

Read more: Diamyd Medical partners with DiaUnion to recruit participants for Type 1 diabetes prevention trial

Cost of diabetes care in US rises to $412.9 billion in 2022 by Michael Monostra for Healio.com/endocrinology, 9 November 2023.

The total annual cost of caring for Americans with diabetes in 2022 was an estimated $412.9 billion, and one in four total healthcare dollars in the U.S. went toward diabetes care, according to the American Diabetes Association in its Economic Costs of Diabetes in the U.S. in 2022 report in Diabetes Care to assess the financial burden for people living with diabetes.

According to the report, overall medical costs for people with diabetes increased by about 7% from 2017 to 2022 after adjusting for inflation. Raveendhara R. Bannuru, MD, PhD, FAGE, vice president of Medical Affairs and quality improvement outcomes, and senior author of the report for the ADA, noted the number of people with diabetes increased in that same period, leading in part to higher expenditures. In 2012, the total cost of diabetes spending was $315.6 billion after adjusting for 2022 dollars.

Want to guess what the numbers will be in 2023?

Read more: Cost of diabetes care in US rises to $412.9 billion in 2022

Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs by Rebecca Pifer for HealthCareDive.com, 10 November 2023. 

Optum Rx, the pharmacy benefits manager operated by healthcare behemoth UnitedHealth, is moving eight popular insulin products to preferred status on its standard formulary for commercially insured Americans. The move, which Optum Rx says will improve access to low-cost insulin, comes as PBMs face hefty congressional scrutiny over their role in raising U.S. drug costs.

Medications on the preferred tier one have the lowest out-of-pocket costs for consumers. Now, all short- and rapid-acting insulins — and the majority of highly prescribed long-acting insulins — will be on that tier, including products from major insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi.

The move is effective January 2024, at which time 98% of all Optum Rx consumers will have access to insulin for $35 or less a month, according to the company. That’s a significant number of people — Optum Rx administers the drug benefit for tens of millions of consumers, according to UnitedHealth.

Read more: Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs

FDA warns people with diabetes to avoid product sold for blood glucose management by Jill Rollet for Healio.com/endocrinology, 6 November 2023.

The FDA issued a warning for consumers to avoid using a nonprescription product currently being sold for blood glucose management due to risks for adverse events, according to an agency press release.

Dr. Ergin’s SugarMD Advanced Glucose Support is a product that can be purchased online at www.sugarmds.com and possibly in some retail stores. The FDA said it conducted a laboratory analysis of the product and confirmed it contains glyburide and metformin, two active ingredients that can be found in several FDA-approved prescription drugs for the treatment of diabetes. The FDA said people who use the product could take a larger combined dose of the diabetes drugs than they intend, which could lead to adverse events. The risk for adverse events is highest for people with chronic kidney disease.

Read more: FDA warns people with diabetes to avoid product sold for blood glucose management

Thermal stability and storage of human insulin by Bernd Richter, Brenda Bongaerts and Maria-Inti Metzendorf as published by CochraneLibrary.com, 6 November 2023.

Health authorities stress the temperature sensitivity of human insulin, advising protection from heat and freezing, with manufacturers suggesting low‐temperature storage for intact vials, and once opened, storage at room temperature for four to six weeks, though usage time and maximum temperature recommendations vary. For human insulin, the recommendations of current shelf life in use may range from 10 to 45 days, and the maximum temperature in use varies between 25 °C and 37 °C.

However, a growing segment of the diabetes‐affected global population resides in challenging environments, confronting prolonged exposure to extreme heat due to the climate crisis, all while grappling with limited access to refrigeration.

Under difficult living conditions, pharmaceutical companies’ data indicate that it is possible to store unopened SAI and IAI vials and cartridges at up to 25 °C for a maximum of six months and at up to 37 °C for a maximum of two months without a clinically relevant loss of insulin potency. Also, oscillating temperatures between 25 °C and 37 °C for up to three months result in no loss of insulin activity for SAI, IAI and MI. In addition, ambient temperature can be lowered by use of simple cooling devices such as clay pots for insulin storage. 

Read more: Thermal stability and storage of human insulin

Every patient deserves to fully understand” – Art, medicine, & T1D with Dr. Mike Natter as presented by Stacey Simms, moderator of Diabetes-Connections.com, 7 November 2023.

Dr. Mike Natter took a non-traditional path to becoming an endocrinologist, starting out as an art student. But it turns out, the universal language of drawing can help break down barriers

Mike lives with type 1 – he was diagnosed at age 9. This is a wide-ranging interview, we talk about his diagnosis at age 9, finishing his medical residency in NYC during the height of COVID, what he learned from his test run with the new Beta Bionics iLet pump, and a lot more.

Listen to the Episode

Or use a free app:

      • bit.ly/DiabetesCxnsApple
      • bit.ly/DiabetesCxnsAndroid
      • bit.ly/DiabetesCxnsSpotify

Antioxidant-rich broccoli sprouts support gut health, lower inflammation by Katharine Lang for MedicalNewsToday.com, 5 November 2023.

Broccoli, kale, collards, cabbage, Brussels sprouts, and mustard greens are cruciferous vegetables or brassicas. A study from Osaka University, published in Redox Biology, found that broccoli sprouts have a significantly higher concentration of polysulfides than mature broccoli five days after germination. Broccoli, kale, collards, cabbage, Brussels sprouts, and mustard greens are cruciferous vegetables or brassicas. 

Scientific evidence supporting the age-old advice to eat your greens is growing, with studies showing that brassicas may help:

Moreover, new evidence suggests those health benefits may be even greater if brassicas, particularly broccoli, are eaten as young sprouts soon after germinating.

Read more: Antioxidant-rich broccoli sprouts support gut health, lower inflammation

Food for Thought … a giggle (but truthful) cartoon by Gina.Pillina (https://www.ginapillina.com/english

Share This
Skip to content